Document text
Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Di seases
Photographs and images included in this presentation a re licensed solely for CDC/NCIRD online and present ation
use. No rights are implied or extended for use in pr inting or any use by other CDC CIOs or any external audiences.
Epidemiology of Respiratory Syncytial Virus Hospitalizations in Adults — RSV-NET Advisory Committee on Immunization Practices, October 2 5, 2023
Monica E. Patton, MD Deputy Lead, RSV-NET Surveillance and Prevention Branch Coronavirus and Other Respiratory Viruses Division
2RESP-NET: RSV-NET, COVID-NET, FluSurv-NET
Active, population-based surveillance of laboratory-confirmed RSV-associated hospitalizations
–>300 acute-care hospitals, 58 counties in 12 states
–~8.6% of U.S. population
Tests positive for RSV within 14 days prior to or during hospitalization
–Clinician-driven testing
Clinical data: random sample of RSV-NET patients stratified by age and site RSV-NET: A RESP-NET population-based hospitalizatio n
surveillance platform
California
Oregon
Utah
Colorado
New Mexico Min nes ota Michigan
Maryland New York
Connecticut
Tennessee
Georgia
RSV-NET surveillance areas with percentage of state population represented by participating RSV-NET counties
3Age groups presented today for adults aged ≥18 year s
Age Group Background/Rationale
18–49 years Youngest adult group 50–59 years Age group for which we are reviewing dat a today
60–64 years 60 is youngest age currently recommended for RSV va ccination, with shared clinical
decision making, in the U.S.
65–74 years 65 is a common definition of “older adults” and use d for other vaccine recommendations
•Certain influenza vaccine formulations
•Universal pneumococcal vaccination
•Age of most Medicare eligibility
≥75 years 75 is the age at which RSV vaccination was recommen ded by the United Kingdom’s Joint
Committee on Vaccination and Immunisation (JCVI)*
*
https://www.gov.uk/government/publications/rsv-immu nisation-programme-jcvi-advice-7-june-2023/respirat ory-syncytial-virus-rsv-immunisation-programme-for- infants-
and-older-adults-jcvi-full-statement-11-september-2 023
Epidemiology of RSV–associated hospitalizations among adults aged 50–59 years
•Demographics
•Rates of RSV-associated hospitalizations
•Underlying medical conditions
•Severe outcomes (ICU admission, mechanical ventilat ion, death)
•Comparison of RSV v. influenza v. COVID-19
•Will not present rates of RSV-associated hospitaliz ations stratified by risk
conditions
5Characteristic Unweighted
N=17,847 Weighted
%
Age (years) 18–49 years 2,435 13.6
50–59 years 2,492 14.0
60–64 years 1,790 10.0 65–74 years 4,079 22.9 ≥75 years 7,051 39.5
Race and ethnicity* White 10,755 62.2 Black 3,529 20.4
Hispanic 1,434 8.3 Asian or Pacific Islander 1,020 5.9 American Indian or Alaska Native 90 0.5 Multirace 89 0.5 Unknown 367 2.1 Characteristics of non-pregnant adults ≥18 years ho spitalized
with lab-confirmed RSV, RSV-NET, 2014–2015 to 2022– 2023
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race. 17,847 hospitalizations over 9 seasons
14% of
hospitalizations in adults aged
50–59 years
6Adjusted RSV-associated hospitalization rates* per 100,000 adults ≥18 years
by 5-year age group and year, RSV-NET, 2015–2016 to 2019–2020
*Unpublished data. Rates are adjusted for the frequ ency of RSV testing during each season and the sens itivity of RSV diagnostic tests. 0100 200 300 400 500 600
18–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 ≥85 Annual RSV-associated hospitalizations per
100,000 population 2015–16 2016–17 2017–18 2018–19 2019–20
26–59
23–42
7050 100 150 200 250
Oct-22
Nov-22
Dec-22
Jan-23
Feb-23
Mar-23
Apr-23
May-23
Jun-23
Jul-23
Aug-23
Sep-23 Rate per 100,000 population Unadjusted monthly and cumulative RSV-associated ho spitalization
rates* among adults ≥18 years — RSV-NET, 2022–2023
010 20 30 40 50 60 70
May-22
Jun-22
Jul-22
Aug-22
Sep-22
Oct-22
Nov-22
Dec-22
Jan-23
Feb-23
Mar-23
Apr-23
May-23
Jun-23
Jul-23
Aug-23
Sep-23 Rate per 100,000 population 18-49 years 50-59 years 60-64 years 65-74 years 75+ years Cumulative rates
October 2022–September 2023 Monthly rates
May 2022–September 2023
*Rates have not been adjusted for RSV testing pract ices and underestimate actual rates of RSV-associat ed hospitalizations, as not all people hospitalized with respiratory illness are tested for RSV; clini cian-driven
testing practices may differ by disease severity, a ge, and/or racial and ethnic group of patients and may have changed over time.
8Underlying medical conditions* among non-pregnant a dults ≥18 years with RSV-
associated hospitalizations — RSV-NET, 2014–2015 to 2017–2018 and 2022–2023
Major underlying condition categories Unweighted
N=7,479 Weighted
%
Cardovascular disease (overall) 5,141 57.4 Obesity 2,798 39.0
Diabetes 2,484 34.1
COPD 2,248 31.4
Heart failure 1,984 28.0
Chronic kidney disease 2,003 27.0
Asthma 1,789 24.0
Coronary artery disease (includes CABG, MI) 1,718 24. 0
Neurologic condition 1,628 22.6
Immune compromised 1,567 20.8
Chronic metabolic disease, not including diabetes 1, 417 19.3
Other chronic lung disease 995 17.1
Chronic liver disease 538 7.2
Autoimmune/inflammatory disease 310 4.5 Blood disorders 287 4.1 94.3% of adults ≥18 years with RSV-associated hospitalization had at least one underlying medical condition: •31.4%: 1–2 conditions
•62.9%: ≥3 conditions
*Clinical data, including underlying medical condit ions, were collected for all patients with laborato ry-confirmed RSV hospitalizations during the 2014–2 015 to 2017–2018 seasons, and for an
age- and site-stratified random sample of patients w ith laboratory-confirmed RSV hospitalizations durin g the 2022–2023 season. Data are presented as unwei ghted case counts and weighted
percentages that were weighted for the probability of selection.
9Underlying medical conditions* among non-pregnant a dults ≥18 years with RSV-
associated hospitalizations — RSV-NET, 2014–2015 to 2017–2018 and 2022–2023
Major underlying condition categories Unweighted
N=7,479 Weighted
%
Cardovascular disease (overall) 5,141 57.4 Obesity 2,798 39.0
Diabetes 2,484 34.1
COPD 2,248 31.4
Heart failure 1,984 28.0
Chronic kidney disease 2,003 27.0
Asthma 1,789 24.0
Coronary artery disease (includes CABG, MI) 1,718 24. 0
Neurologic condition 1,628 22.6
Immune compromised 1,567 20.8
Chronic metabolic disease, not including diabetes 1, 417 19.3
Other chronic lung disease 995 17.1
Chronic liver disease 538 7.2
Autoimmune/inflammatory disease 310 4.5 Blood disorders 287 4.1 94.3% of adults ≥18 years with RSV-associated hospitalization had at least one underlying medical condition: •31.4%: 1–2 conditions
•62.9%: ≥3 conditions
*Clinical data, including underlying medical condit ions, were collected for all patients with laborato ry-confirmed RSV hospitalizations during the 2014–2 015 to 2017–2018 seasons, and for an
age- and site-stratified random sample of patients w ith laboratory-confirmed RSV hospitalizations durin g the 2022–2023 season. Data are presented as unwei ghted case counts and weighted
percentages that were weighted for the probability of selection.
100 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
*Clinical data were collected for all patients with l aboratory-confirmed RSV hospitalizations during the 2014 –2015 to 2017–2018 seasons, and for an age- and site-st ratified random sample of patients with laboratory-confi rmed RSV hospitalizations during the
2022–2023 season. Displayed percentages were weighte d for the probability of selection. 18–49 years
0 20 40 60 80 100 50–59 years
0 20 40 60 80 100 60–64 years
0 20 40 60 80 100 65–74 years
0 20 40 60 80 100 120 ≥75 years
Percent Percent Percent Percent Percent
1114
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
4
0 20 40 60 80 100 50–59 years
4
0 20 40 60 80 100 60–64 years
4
0 20 40 60 80 100 65–74 years
4
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. Percent Percent Percent Percent Percent
1286
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
96
0 20 40 60 80 100 50–59 years
96
0 20 40 60 80 100 60–64 years
96
0 20 40 60 80 100 65–74 years
96
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. Percent Percent Percent Percent Percent
1344
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
38
0 20 40 60 80 100 50–59 years
33
0 20 40 60 80 100 60–64 years
27
0 20 40 60 80 100 65–74 years
26
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. Percent Percent Percent Percent Percent
1442
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
58
0 20 40 60 80 100 50–59 years
63
0 20 40 60 80 100 60–64 years
69
0 20 40 60 80 100 65–74 years
69
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection.Percent Percent Percent Percent Percent
1553
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
44
0 20 40 60 80 100 50–59 years
49
0 20 40 60 80 100 60–64 years
62
0 20 40 60 80 100 65–74 years
75
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. Percent Percent Percent Percent Percent
1653
32
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
44
43
0 20 40 60 80 100 50–59 years
44
49
0 20 40 60 80 100 60–64 years
47
62
0 20 40 60 80 100 65–74 years
75
36
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. Percent Percent Percent Percent Percent
1753
32
25
0 20 40 60 80 100 No medical condition
≥1 medical condition
1-2 conditions
>=3 conditions
Obesity
Cardovascular disease…
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease…
Chronic metabolic disease,…
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory… Frequency of underlying medical conditions among no n-pregnant adults with RSV-
associated hospitalizations by age group — RSV-NET, 2014–2015 to 2017–2018 and
2022–2023
18–49 years
44
43
37
0 20 40 60 80 100 50–59 years
44
49
41
0 20 40 60 80 100 60–64 years
47
62
42
0 20 40 60 80 100 65–74 years
75
33
36
33
0 20 40 60 80 100 120 ≥75 years
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. Percent Percent Percent Percent Percent
18Prevalence of certain medical conditions *among non-pregnant adults with RSV-
associated hospitalizations (RSV-NET, 2014–2015 to 2017–2018 and 2022–2023) and
among the general population (National Center for H ealth Statistics †, 2022) by age
group
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV
hospitalizations during the 2022–2023 season. Displ ayed percentages were weighted for the probability of selection.
†National Center for Health Statistics. United State s, 2022. National Health Interview Survey. Generated interactively: Oct 17, 2023 from https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/ind ex.html 50–64 years ≥65 years
General
population RSV-NET RSV-
NET/
Pop General
population RSV-NET RSV-
NET/
Pop Condition % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Coronary artery disease 5.0 (4.4, 5.6) 18.9 (16.9, 21.0) 3.8 15.3 (14.4, 16.2) 31.3 (29.1, 33.6) 2.0
COPD 6.2 (5.5, 6.9) 35.4 (32.9, 37.9) 5.7 9.8 (9.1, 10.5) 33.2 (30.1, 35.5) 3.4
Diabetes mellitus 13.8 (12.9, 14.7) 37.7 (35.1, 40.4) 2.7 20.1 (19.1, 21.1) 31.8 (29.6, 34.1) 1.6
Asthma 9.1 (8.4, 9.9) 28.6 (26.3, 31.0) 3.1 8.0 (7.3, 8.6) 17.6 (15.8, 19.4) 2.2
Obesity 37.6 (36.2, 38.9) 46.4 (43.7, 49.0) 1.2 30.4 (29.2, 31.6) 28.4 (26.1, 30.8) 0.9
19Frequency of underlying medical conditions among ad ults aged 50–59 years with ICU
admissions and RSV-associated hospitalizations — RSV -NET, 2014–2015 to 2017–2018 and
2022–2023
ICU admissions Hospitalizations
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. 0 20 40 60 80 100 No medical condition
≥1 medical condition
Cardovascular disease (overall)
Obesity
Diabetes
COPD
Heart failure
Immune compromised
Chonic kidney disease
Asthma
Coronary artery disease (includes CABG, MI)
Other chronic lung disease
Neurologic condition
Chronic liver disease
Chronic metabolic disease, not including diabetes
Blood disorders
Autoimmune/inflammatory disease
0 20 40 60 80 100 No medical condition
≥1 medical condition
Obesity
Cardovascular disease (overall)
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease (includes CABG, MI)
Chronic metabolic disease, not including diabetes
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory disease
Percent Percent
20Frequency of underlying medical conditions among ad ults aged 50–59 years with ICU
admissions and RSV-associated hospitalizations — RSV -NET, 2014–2015 to 2017–2018 and
2022–2023
ICU admissions Hospitalizations
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. 4
95
49
44
40
35
30
29
26
25
19
17
16
14
11
4
2
0 20 40 60 80 100 No medical condition
≥1 medical condition
Cardovascular disease (overall)
Obesity
Diabetes
COPD
Heart failure
Immune compromised
Chonic kidney disease
Asthma
Coronary artery disease (includes CABG, MI)
Other chronic lung disease
Neurologic condition
Chronic liver disease
Chronic metabolic disease, not including diabetes
Blood disorders
Autoimmune/inflammatory disease 4
96
44
43
37
31
29
26
23
21
17
17
15
12
10
5
4
0 20 40 60 80 100 No medical condition
≥1 medical condition
Obesity
Cardovascular disease (overall)
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease (includes CABG, MI)
Chronic metabolic disease, not including diabetes
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory disease
Percent Percent
21Frequency of underlying medical conditions among ad ults aged 50–59 years with ICU
admissions and RSV-associated hospitalizations — RSV -NET, 2014–2015 to 2017–2018 and
2022–2023
ICU admissions Hospitalizations
*Clinical data were collected for all patients with laboratory-confirmed RSV hospitalizations during t he 2014–2015 to 2017–2018 seasons, and for an age- a nd site-stratified random sample of patients with l aboratory-confirmed RSV hospitalizations during the 2022–2023 season. Displayed
percentages were weighted for the probability of se lection. 4
95
49
44
40
35
30
29
26
25
19
17
16
14
11
4
2
0 20 40 60 80 100 No medical condition
≥1 medical condition
Cardovascular disease (overall)
Obesity
Diabetes
COPD
Heart failure
Immune compromised
Chonic kidney disease
Asthma
Coronary artery disease (includes CABG, MI)
Other chronic lung disease
Neurologic condition
Chronic liver disease
Chronic metabolic disease, not including diabetes
Blood disorders
Autoimmune/inflammatory disease 4
96
44
43
37
31
29
26
23
21
17
17
15
12
10
5
4
0 20 40 60 80 100 No medical condition
≥1 medical condition
Obesity
Cardovascular disease (overall)
Diabetes
COPD
Asthma
Immune compromised
Heart failure
Chonic kidney disease
Neurologic condition
Coronary artery disease (includes CABG, MI)
Chronic metabolic disease, not including diabetes
Other chronic lung disease
Chronic liver disease
Blood disorders
Autoimmune/inflammatory disease
Percent Percent
22Percentages of non-pregnant adults ≥18 years with R SV-associated
hospitalization who experienced severe outcomes by a ge group, RSV-NET,
2022–2023
16% 21%
16% 21%
15%
4% 10%
4% 6%
4%
2% 3%
2% 4% 6%
0% 5% 10% 15% 20% 25%
18–49 50–59 60–64 65–74 ≥75 Proportion of Hospitalized Adults with Severe
Outcome ICU Mechanical ventilation Died
ICU = intensive care unit *Clinical data, including severe outcomes, were col lected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospital izations during the 2022–2023 season.
Displayed percentages were weighted for the probabi lity of selection.
2316 21
16 21
15 17 18
18
17
11 16 21
20
19
11
0510 15 20 25
18–49 50–59 60–64 65–74 ≥75 Proportion of Hospitalizations Admitted to ICU RSV Influenza COVID Percentages of non-pregnant adults ≥18 years with l aboratory-confirmed
hospitalization admitted to intensive care unit (ICU) , RSV-NET, FluSurv-NET,
COVID-NET, 2022–2023
*Clinical data, including severe outcomes, were coll ected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV, Influenz a, and COVID-19 hospitalizations during the 2022–20 23 season. Displayed percentages
were weighted for the probability of selection. †Patients with severe disease may be more likely to b e tested for RSV, Influenza, or COVID-19 which may overestimate proportions of patients admitted to the ICU.
‡Data shown here does not take patient vaccination or treatment status into account.
§FluSurv-NET surveillance occurred during October 202 2–April 2023; RSV-NET and COVID-NET surveillance occ urred year-round.
2423
246
13
335
1346
4
01234567
18–49 50–59 60–64 65–74 ≥75 Proportion of Hospitalizatizations with In-hospital
Death RSV Influenza COVID Percentages of non-pregnant adults ≥18 years with l aboratory-confirmed
hospitalization with in-hospital death *, RSV-NET, FluSurv-NET, COVID-NET,
2022–2023
*Clinical data, including severe outcomes, were coll ected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV, Influenz a, and COVID-19 hospitalizations during the 2022–20 23 season. Displayed percentages
were weighted for the probability of selection. †Patients with severe disease may be more likely to b e tested for RSV, Influenza, or COVID-19 which may overestimate proportions of patients admitted to the ICU.
‡Data shown here does not take patient vaccination or treatment status into account.
§FluSurv-NET surveillance occurred during October 202 2–April 2023; RSV-NET and COVID-NET surveillance occ urred year-round.
25Distribution of RSV-associated hospitalizations and severe outcomes
among adults ≥18 years by age group, RSV-NET, 2022–2 023
17% 15% 13% 8% 12% 14% 22%
9% 9% 9% 7%
4% 23% 28% 26%
22% 39% 33% 31%
58%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Hospitalizations ICU Mechanical ventilation Death Proportion 18–49 50–59 60–64 65–74 ≥75
ICU = intensive care unit *Clinical data, including severe outcomes, were col lected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospital izations during the 2022–2023
season. Displayed percentages were weighted for the probability of selection.
26Distribution of RSV-associated hospitalizations and severe outcomes
among adults ≥18 years by age group, RSV-NET, 2022–2 023
17% 15% 13% 8% 12% 14% 22%
9% 9% 9% 7%
4% 23% 28% 26%
22% 39% 33% 31%
58%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Hospitalizations ICU Mechanical ventilation Death Proportion 18–49 50–59 60–64 65–74 ≥75
ICU = intensive care unit *Clinical data, including severe outcomes, were col lected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospital izations during the 2022–2023
season. Displayed percentages were weighted for the probability of selection.
27Distribution of RSV-associated hospitalizations and severe outcomes
among adults ≥18 years by age group, RSV-NET, 2022–2 023
17% 15% 13% 8% 12% 14% 22%
9% 9% 9% 7%
4% 23% 28% 26%
22% 39% 33% 31%
58%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Hospitalizations ICU Mechanical ventilation Death Proportion 18–49 50–59 60–64 65–74 ≥75
ICU = intensive care unit *Clinical data, including severe outcomes, were col lected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospital izations during the 2022–2023
season. Displayed percentages were weighted for the probability of selection.
28Distribution of RSV-associated hospitalizations and severe outcomes
among adults ≥18 years by age group, RSV-NET, 2022–2 023
17% 15% 13% 8% 12% 14% 22%
9% 9% 9% 7%
4% 23% 28% 26%
22% 39% 33% 31%
58%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Hospitalizations ICU Mechanical ventilation Death Proportion 18–49 50–59 60–64 65–74 ≥75
ICU = intensive care unit *Clinical data, including severe outcomes, were col lected for an age- and site-stratified random sample of patients with laboratory-confirmed RSV hospital izations during the 2022–2023
season. Displayed percentages were weighted for the probability of selection.
29Median age of non-pregnant adults ≥18 years with RS V-associated
hospitalizations by race and ethnicity* — RSV-NET, 2 014–2015 to 2022–
2023
Unweighted Weighted
%Median Age Interquartile
range (IQR)
Overall 17,847 - 69 (58–81)
White 10,755 62.2 73 (63-82)
Black 3,529 20.4 62 (50-71)
Hispanic 1,434 8.3 62 (48-76)
Asian or Pacific Islander 1,020 5.9 73 (59-83)
American Indian or Alaska Native 90 0.5 64 (54-73)
Multirace 89 0.5 75 (58-84)
Unknown 367 2.1 68 (57-78)
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
30Median age of non-pregnant adults ≥18 years with RS V-associated
hospitalizations by race and ethnicity* — RSV-NET, 2 014–2015 to 2022–
2023
Unweighted Weighted
%Median Age Interquartile
range (IQR)
Overall 17,847 - 69 (58–81)
White 10,755 62.2 73 (63-82)
Black 3,529 20.4 62 (50-71)
Hispanic 1,434 8.3 62 (48-76)
Asian or Pacific Islander 1,020 5.9 73 (59-83)
American Indian or Alaska Native 90 0.5 64 (54-73)
Multirace 89 0.5 75 (58-84)
Unknown 367 2.1 68 (57-78)
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
31Distribution of RSV-associated hospitalizations amon g adults ≥18 years by
race and ethnicity *and age group— RSV-NET, 2014–2015 to 2022–2023
39% 53% 62% 69% 79% 29% 23% 21% 17% 7%
18% 13% 8% 6% 5% 8% 6% 5% 5% 6%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
18–49 50–59 60–64 65–74 ≥75 Proportion White Black Hispanic Asian or Pacific Islander
*Black, White, and Asian/Pacific Islander people we re categorized as non-Hispanic; Hispanic people cou ld be of any race. American Indian/Alaska Native pe rsons are not shown
due to small numbers.
32Distribution of RSV-associated ICU admissions among ad ults ≥18 years by
race and ethnicity * and age group — RSV-NET, 2014–2015 to 2022–2023
41% 60% 58% 69% 75% 39% 22% 30% 19% 9% 11% 8% 8% 6% 8% 9% 9% 5% 5% 8%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
18–49 50–59 60–64 65–74 ≥75 Proportion White Black Hispanic Asian or Pacific Islander
*Black, White, and Asian/Pacific Islander people we re categorized as non-Hispanic; Hispanic people cou ld be of any race. American Indian/Alaska Native pe rsons are not shown
due to small numbers.
33Burden-adjusted hospitalization rate ratios among ad ults ≥18 years by race
and ethnicity* — RSV-NET, 2016–2017 to 2019–2020
Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20)
01234
18–49 50–59 60–64 65–74 ≥75 White
Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20)
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
34
01234
18–49 50–59 60–64 65–74 ≥75 White Hispanic Burden-adjusted hospitalization rate ratios among ad ults ≥18 years by race
and ethnicity* — RSV-NET, 2016–2017 to 2019–2020
Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20)
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
35
01234
18–49 50–59 60–64 65–74 ≥75 Asian or Pacific Islander White Hispanic Burden-adjusted hospitalization rate ratios among ad ults ≥18 years by race
and ethnicity* — RSV-NET, 2016–2017 to 2019–2020
Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20)
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
36Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20)
01234
18–49 50–59 60–64 65–74 ≥75 Asian or Pacific Islander White Hispanic Black Burden-adjusted hospitalization rate ratios among ad ults ≥18 years by race
and ethnicity* — RSV-NET, 2016–2017 to 2019–2020
Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20)
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
37
01234
18–49 50–59 60–64 65–74 ≥75 Asian or Pacific Islander White Hispanic Black American Indian or Alaska Native
Maximum rate ratio (2016–17 to 2019–20)
Average rate ratio (2016–17 to 2019–20) Minimum rate ratio (2016–17 to 2019–20) Burden-adjusted hospitalization rate ratios among ad ults ≥18 years by race
and ethnicity* — RSV-NET, 2016–2017 to 2019–2020
*Black, White, American Indian/Alaska Native and As ian/Pacific Islander people were categorized as non -Hispanic; Hispanic people could be of any race.
38Coronavirus and Other Respiratory
Viruses Division
Amadea Britton Fiona Havers Michael Melgar Kadam Patel Huong Pham Chris Taylor Michael Whitaker Influenza Division
Alissa O’Halloran Catherine Bozio Dawud Ujamaa RESP-NET Site Investigators and Staff Acknowledgements
For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov
The findings and conclusions in this report are tho se of the authors and do not necessarily represent the official
position of the Centers for Disease Control and Pre vention.
Photographs and images included in this presentatio n are licensed solely for CDC/NCIRD online and pres entation
use. No rights are implied or extended for use in p rinting or any use by other CDC CIOs or any externa l audiences.